PURPOSE: Capecitabine is a relatively new oral fluoropyrimidine currently licensed for the treatment of colorectal and breast cancer. RESULTS: It has the advantage of oral administration with good tolerability and comparable activity to intravenous 5-fluorouracil. Central neurotoxicity has been described in 5-fluorouracil-treated patients but there is little data regarding capecitabine. We report here a case of reversible capecitabine-induced encephalopathy progressing to coma. DISCUSSION: Literature on fluoropyrimidine-related neurotoxicity will also be reviewed and possible mechanisms of the drug or its metabolites crossing the blood-brain barrier will be discussed.
PURPOSE:Capecitabine is a relatively new oral fluoropyrimidine currently licensed for the treatment of colorectal and breast cancer. RESULTS: It has the advantage of oral administration with good tolerability and comparable activity to intravenous 5-fluorouracil. Central neurotoxicity has been described in 5-fluorouracil-treated patients but there is little data regarding capecitabine. We report here a case of reversible capecitabine-induced encephalopathy progressing to coma. DISCUSSION: Literature on fluoropyrimidine-related neurotoxicity will also be reviewed and possible mechanisms of the drug or its metabolites crossing the blood-brain barrier will be discussed.
Authors: Neal Shah; Afroz S Mohammad; Pushkar Saralkar; Samuel A Sprowls; Schuyler D Vickers; Devin John; Rachel M Tallman; Brandon P Lucke-Wold; Katherine E Jarrell; Mark Pinti; Richard L Nolan; Paul R Lockman Journal: Pharmacol Res Date: 2018-03-28 Impact factor: 7.658
Authors: Timothy F Cloughesy; Joseph Landolfi; Daniel J Hogan; Stephen Bloomfield; Bob Carter; Clark C Chen; J Bradley Elder; Steven N Kalkanis; Santosh Kesari; Albert Lai; Ian Y Lee; Linda M Liau; Tom Mikkelsen; Phioanh Leia Nghiemphu; David Piccioni; Tobias Walbert; Alice Chu; Asha Das; Oscar R Diago; Dawn Gammon; Harry E Gruber; Michelle Hanna; Douglas J Jolly; Noriyuki Kasahara; David McCarthy; Leah Mitchell; Derek Ostertag; Joan M Robbins; Maria Rodriguez-Aguirre; Michael A Vogelbaum Journal: Sci Transl Med Date: 2016-06-01 Impact factor: 17.956
Authors: Zhi-Gang Jiang; Gordon Winocur; J Martin Wojtowicz; Olga Shevtsova; Steven Fuller; Hossein A Ghanbari Journal: PLoS One Date: 2018-01-25 Impact factor: 3.240